Phase I Trial of OPB-111077 in Combination With Decitabine for the Treatment of AML Refractory to or Ineligible for Intensive Chemotherapy
Phase of Trial: Phase I
Latest Information Update: 30 Apr 2018
At a glance
- Drugs Decitabine (Primary) ; OPB 111077 (Primary)
- Indications Myeloid leukaemia
- Focus Adverse reactions
- 23 Apr 2018 Status changed from recruiting to suspended due to second DLT in cohort experience. Cohort is closed and study is being amended in order to re-open
- 08 Nov 2017 Status changed from active, no longer recruiting to recruiting.
- 03 Oct 2017 Status changed from recruiting to active, no longer recruiting.